Lymphoma Cancer

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

In this week’s episode of the CURE Talks Cancer podcast, Maryland Governor Larry Hogan opens up about what it was like to go through cancer not once but twice, and why he considers every day a gift.
 

Here, a survivor lists some alternative ways that patients with cancer or survivors in need of flexible employment can earn extra money.

Ethan Zohn, "Survivor: Africa" winner, discusses how his winner’s mentality helped him through treatment and how leaning on others has been key in survivorship.
 

“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.
 

From a new trial in Canada looking at therapeutics to help prevent severe symptoms of COVID-19 in patients with cancer to updated guidelines from the American Cancer Society on taking the HPV vaccine to prevent certain cancers, here’s what’s making the headlines in the cancer space this week.
 

“Let's try to make something good out of something really bad,” says “Survivor: Africa” winner, and lymphoma survivor, Ethan Zohn.
 

The Food and Drug Administration has had a busy couple of weeks, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
 

The Food and Drug Administration granted accelerated approval to Xpovio for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who have undergone two prior therapies.
 

The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.